Results 141 to 150 of about 13,106 (183)
XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis. [PDF]
Cell Commun SignalXu TT +8 more
europepmc +1 more source
Remodeling of the bone marrow vasculature induced by venetoclax and azacitidine damage. [PDF]
BloodNgo S +8 more
europepmc +1 more source
Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML. [PDF]
Blood AdvBaeten JT +13 more
europepmc +1 more source
Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine. [PDF]
Am J HematolKonopleva M +8 more
europepmc +1 more source
Azacitidine as maintenance therapy in pediatric <i>de novo</i> acute myeloid leukemia. [PDF]
Front ImmunolWu C +5 more
europepmc +1 more source
Ivosidenib for cholangiocarcinoma and acute myeloid leukaemia. [PDF]
Aust Prescreuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Reviews Drug Discovery, 2005
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status.
Jean-Pierre J, Issa +2 more
+7 more sources
Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status.
Jean-Pierre J, Issa +2 more
+7 more sources